Terms: = Breast cancer AND IL7R, P16871, IL-7R-alpha, CDW127, CD127, ENSG00000168685, 3575 AND Treatment
17 results:
1. Effect of Peripheral Blood Lymphocytes on Prognosis of Multiple cancers.
Zhang X; Jing J
Cancer Control; 2023; 30():10732748231202921. PubMed ID: 37815060
[TBL] [Abstract] [Full Text] [Related]
2. The influence of a supervised group exercise intervention combined with active lifestyle recommendations on breast cancer survivors' health, physical functioning, and quality of life indices: study protocol for a randomized and controlled trial.
Riani Costa LA; F Barreto R; de Leandrini SMM; Gurgel ARB; de Sales GT; Voltarelli VA; de Castro G; Fenton SAM; Turner JE; Klausener C; Neves LM; Ugrinowitsch C; Farah JC; Forjaz CLM; Brito CMM; Brum PC
Trials; 2021 Dec; 22(1):934. PubMed ID: 34922621
[TBL] [Abstract] [Full Text] [Related]
3. Peripheral blood immune markers in breast cancer: Differences in regulatory T cell abundance are related to clinical parameters.
Jørgensen N; Lænkholm AV; Sækmose SG; Hansen LB; Hviid TVF
Clin Immunol; 2021 Nov; 232():108847. PubMed ID: 34506945
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathological characteristics and prognostic marker of triple-negative breast cancer in older women.
Honma N; Ogata H; Yamada A; Matsuda Y; Kontani K; Miyashita M; Arai T; Sasaki E; Shibuya K; Mikami T; Sawaki M
Hum Pathol; 2021 May; 111():10-20. PubMed ID: 33548251
[TBL] [Abstract] [Full Text] [Related]
5. Notch signaling pathway regulates CD4
Yang L; Zhao KL; Qin L; Ji DX; Zhang B; Zheng PF; Qin YM
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988066
[TBL] [Abstract] [Full Text] [Related]
6. Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
Ibrahim M; Yadav S; Ogunleye F; Zakalik D
BMC Cancer; 2018 Feb; 18(1):179. PubMed ID: 29433453
[TBL] [Abstract] [Full Text] [Related]
7. Impact of obesity and exercise on chemotherapy-related fatigue.
Herath K; Peswani N; Chitambar CR
Support Care Cancer; 2016 Oct; 24(10):4257-62. PubMed ID: 27146493
[TBL] [Abstract] [Full Text] [Related]
8. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Cuzick J; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A; Forbes JF;
Lancet Oncol; 2015 Jan; 16(1):67-75. PubMed ID: 25497694
[TBL] [Abstract] [Full Text] [Related]
9. Circulating regulatory T cells of cancer patients receiving radiochemotherapy may be useful to individualize cancer treatment.
Schmidt MA; Förtsch C; Schmidt M; Rau TT; Fietkau R; Distel LV
Radiother Oncol; 2012 Jul; 104(1):131-8. PubMed ID: 22682747
[TBL] [Abstract] [Full Text] [Related]
10. Development of an instrument to measure adherence to strength training in postmenopausal breast cancer survivors.
Huberty JL; Vener J; Waltman N; Ott C; Twiss J; Gross G; McGuire R; Dwyer A
Oncol Nurs Forum; 2009 Sep; 36(5):E266-73. PubMed ID: 19726386
[TBL] [Abstract] [Full Text] [Related]
11. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
[TBL] [Abstract] [Full Text] [Related]
12. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
[TBL] [Abstract] [Full Text] [Related]
13. Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma.
Ambrus JL; Dembinski W; Ambrus JL; Sykes DE; Akhter S; Kulaylat MN; Islam A; Chadha KC
Cancer; 2003 Dec; 98(12):2730-3. PubMed ID: 14669296
[TBL] [Abstract] [Full Text] [Related]
14. A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer.
Mustacchi G; Muggia M; Milani S; Ceccherini R; Leita ML; Dellach C
Ann Oncol; 2002 Nov; 13(11):1730-6. PubMed ID: 12419744
[TBL] [Abstract] [Full Text] [Related]
15. High-dose toremifene in advanced renal-cell carcinoma.
Gershanovich MM; Moiseyenko VM; Vorobjev AV; Käpylä H; Ellmén J; Anttila M
Cancer Chemother Pharmacol; 1997; 39(6):547-51. PubMed ID: 9118468
[TBL] [Abstract] [Full Text] [Related]
16. [Hormone therapy of advanced renal cancer with high-dose toremifene (Fareston)].
Gershanovich ML; Moiseenko VM; Vorob'ev AV; Kiapiulia K
Vopr Onkol; 1996; 42(5):105-9. PubMed ID: 9064893
[TBL] [Abstract] [Full Text] [Related]
17. Diphtheria toxin-based receptor-specific chimaeric toxins as targeted therapies.
Sweeney EB; Murphy JR
Essays Biochem; 1995; 30():119-31. PubMed ID: 8822152
[TBL] [Abstract] [Full Text] [Related]
